Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Ulerythema ophryogenesis is characterized by inflammatory keratotic papules occurring on the face, which may be followed by scars, atrophy and alopecia. Prevalence is unknown but the disease, affecting mainly children and young adults, is rare. Erythema with mild hyperkeratosis of the hair follicles resulting in rough papules is observed on the cheeks and lateral aspects of the eyebrows. The disorder occasionally extends to the adjacent scalp, ears and forehead and rarely to the extensor surfaces of the limbs. Symptoms regress with age, although loss of the lateral aspects of the eyebrows can occur. Many cases occur sporadically; autosomal dominant inheritance has also been reported. There is no particular treatment, but patients should avoid sun exposure without UV protection.
Biomarker and diagnostic research for ulerythema ophryogenesis has been reported in the published literature.
Estimated prevalence: Unknown (Unknown prevalence).
No clinical trials have been registered for ulerythema ophryogenesis.
165 publications have been identified in PubMed for ulerythema ophryogenesis. Research spans Basic Science / Preclinical (33%), Review / Meta-Analysis (25%), and Clinical Trial Publication (16%).
Research Type | Count | % of Total |
|---|---|---|
Laboratory research | 55 | 33% |
Data assembled from 3 of 12 sources · Last updated Sep 20, 2026, 8:40 AM UTC
European rare disease database
Genetic and Rare Diseases Info Center
42 |
25% |
Clinical study results | 27 | 16% |
Patient case studies | 13 | 8% |
Testing and diagnosis research | 10 | 6% |
New treatment approaches | 9 | 5% |
Disease patterns and progression | 7 | 4% |
Other research | 2 | 1% |
D'Avino P (2026). [PMID: 40985485](https://pubmed.ncbi.nlm.nih.gov/40985485/). *Allergy*. [Basic Science / Preclinical]
Liu F (2026). [PMID: 41439609](https://pubmed.ncbi.nlm.nih.gov/41439609/). *Journal of cosmetic dermatology*. [Clinical Trial Publication]
Awad A (2026). [PMID: 41496469](https://pubmed.ncbi.nlm.nih.gov/41496469/). *Experimental dermatology*. [Case Report / Case Series]
Kumskova M (2026). [PMID: 41284637](https://pubmed.ncbi.nlm.nih.gov/41284637/). *Blood*. [Basic Science / Preclinical]
Fiumara M (2026). [PMID: 41175032](https://pubmed.ncbi.nlm.nih.gov/41175032/). *Curr Opin Rheumatol*. [Review / Meta-Analysis]
Du YJ (2026). [PMID: 41736049](https://pubmed.ncbi.nlm.nih.gov/41736049/). *Trials*. [Clinical Trial Publication]
Xing Y (2026). [PMID: 41741647](https://pubmed.ncbi.nlm.nih.gov/41741647/). *Nature*. [Basic Science / Preclinical]
George A (2025). [PMID: 41031738](https://pubmed.ncbi.nlm.nih.gov/41031738/). *Invest Ophthalmol Vis Sci*. [Basic Science / Preclinical]
Shirley M (2025). [PMID: 40095376](https://pubmed.ncbi.nlm.nih.gov/40095376/). *Drugs*. [Review / Meta-Analysis]
Goldbach-Mansky R (2025). [PMID: 39623155](https://pubmed.ncbi.nlm.nih.gov/39623155/). *Nature reviews. Rheumatology*. [Review / Meta-Analysis]